ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of next-generation medical countermeasures (MCMs) to protect Americans from public health security threats such as coronaviruses.
FDA questions off-target edit testing on Vertex and CRISPR’s potential sickle cell gene therapy ahead of adcomm
The FDA is convening an advisory committee next Tuesday to discuss whether Vertex Pharmaceuticals and CRISPR Therapeutics did enough to adequately measure the off-target alterations
October 28, 2023